SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gains on launching RT-PCR test kit ‘ViraGen’ for COVID-19 in India

20 May 2021 Evaluate

Cipla is currently trading at Rs. 912.85, up by 8.80 points or 0.97% from its previous closing of Rs. 884.15 on the BSE.

The scrip opened at Rs. 906.00 and has touched a high and low of Rs. 913.05 and Rs. 905.00 respectively. So far 7287 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 966.00 on 20-Apr-2021 and a 52 week low of Rs. 595.00 on 20-May-2020.

Last one week high and low of the scrip stood at Rs. 920.95 and Rs. 870.00 respectively. The current market cap of the company is Rs. 72911.04 crore.

The promoters holding in the company stood at 36.73%, while Institutions and Non-Institutions held 40.43% and 22.84% respectively.

Cipla has launched a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems. ViraGen is the company’s third offering in the Covid-19 testing segment. It already has partnerships for antibody detection kit and antigen test kits.

This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19. ViraGen used for qualitative detection of SARS-CoV-2 will be manufactured by Ubio Biotechnology Systems and marketed and distributed by Cipla through its expansive distribution network across the country.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1309.90 -6.75 (-0.51%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×